a2-binding peptide has been researched along with Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender, A; Bröcker, EB; Cerundolo, V; Dieckmann, D; Dunbar, R; Enk, A; Haendle, I; Jonuleit, H; Kämpgen, E; Keikavoussi, P; Knop, J; Leisgang, W; Maczek, C; Röder, C; Schuler, G; Schuler-Thurner, B; von Den Driesch, P | 1 |
1 trial(s) available for a2-binding peptide and Melanoma
| Article | Year |
|---|---|
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.
Topics: Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Cytotoxicity, Immunologic; Dendritic Cells; Epitopes, T-Lymphocyte; Humans; Immunization, Secondary; Injections, Intravenous; Injections, Subcutaneous; Intercellular Signaling Peptides and Proteins; Lymphocyte Activation; Melanoma; Monocytes; Neoplasm Proteins; Peptides; T-Lymphocytes, Cytotoxic; Tetanus Toxoid; Viral Matrix Proteins | 2000 |